Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BB709 + BB711 + BB712 + BB713 + BB714 + BB715 + BB716 + BB717 + BB718 + BB719 + BB720
- Development stage
- Preclinical
- Lead developer
- BalinBac Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Inhalation
01
Overview
The BB-700 series (specifically the combination of BB709, BB711, BB712, BB713, BB714, BB715, BB716, BB717, BB718, BB719, and BB720) is an experimental multi-drug combination therapy being developed by BalinBac Therapeutics for the treatment of COVID-19. This preclinical-stage candidate utilizes eleven repurposed generic small molecules to target the SARS-CoV-2 virus through multiple complementary pathways. The mechanism of action involves a multi-pronged approach including the inhibition of the viral spike protein, entry/attachment, main protease, and RNA-dependent RNA polymerase, alongside the modulation of host metabolic responses and enzyme activation. The combination is designed for administration via both oral and inhalation routes to maximize therapeutic efficacy against the infection.
- Other names
- BB-700 seriesBB700 seriesBB 700 series
02
Targets
Mpro (3C-like proteinase of SARS-CoV-2)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on BB709 + BB711 + BB712 + BB713 + BB714 + BB715 + BB716 + BB717 + BB718 + BB719 + BB720.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BB709 + BB711 + BB712 + BB713 + BB714 + BB715 + BB716 + BB717 + BB718 + BB719 + BB720.